- Report
- April 2025
- 85 Pages
Saudi Arabia
From €3173EUR$3,500USD£2,745GBP
- Report
- December 2024
- 85 Pages
Spain
From €3173EUR$3,500USD£2,745GBP
- Report
- September 2024
- 80 Pages
France
From €3173EUR$3,500USD£2,745GBP
- Report
- August 2024
- 80 Pages
Japan
From €3173EUR$3,500USD£2,745GBP
From €3173EUR$3,500USD£2,745GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3400EUR$3,750USD£2,941GBP
- Report
- November 2023
- 30 Pages
Global
From €2493EUR$2,750USD£2,157GBP
- Report
- November 2023
- 30 Pages
Global
From €2493EUR$2,750USD£2,157GBP
- Report
- January 2022
- 90 Pages
Global
From €1813EUR$2,000USD£1,569GBP
- Report
- February 2024
- 80 Pages
Latin America
From €4306EUR$4,750USD£3,725GBP
- Report
- October 2022
- 202 Pages
Europe
From €3128EUR$3,450USD£2,706GBP
- Report
- July 2022
- 255 Pages
Global
From €4034EUR$4,450USD£3,490GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4306EUR$4,750USD£3,725GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4306EUR$4,750USD£3,725GBP
- Report
- March 2019
- 90 Pages
Europe
From €4306EUR$4,750USD£3,725GBP
- Report
- October 2022
- 205 Pages
Asia Pacific
From €3128EUR$3,450USD£2,706GBP
- Report
- October 2022
- 181 Pages
Middle East, Africa
From €3128EUR$3,450USD£2,706GBP
- Report
- October 2022
- 177 Pages
From €3128EUR$3,450USD£2,706GBP
- Report
- October 2022
- 174 Pages
North America
From €3128EUR$3,450USD£2,706GBP
- Report
- February 2024
- 150 Pages
Global
From €4306EUR$4,750USD£3,725GBP

The Human Insulin market is a segment of the Endocrine and Metabolic Disorders Drugs market. It is composed of drugs used to treat diabetes, a condition in which the body does not produce enough insulin or is unable to use the insulin it produces. Human Insulin is a synthetic form of insulin, which is produced in a laboratory and is identical to the insulin produced by the human body. It is used to treat both type 1 and type 2 diabetes. Human Insulin is available in a variety of forms, including short-acting, intermediate-acting, and long-acting. It is typically administered via injection or an insulin pump.
Some companies in the Human Insulin market include Novo Nordisk, Sanofi, Eli Lilly, and Biocon. Show Less Read more